149 related articles for article (PubMed ID: 36047147)
41. Advances in microfluidic in vitro systems for neurological disease modeling.
Holloway PM; Willaime-Morawek S; Siow R; Barber M; Owens RM; Sharma AD; Rowan W; Hill E; Zagnoni M
J Neurosci Res; 2021 May; 99(5):1276-1307. PubMed ID: 33583054
[TBL] [Abstract][Full Text] [Related]
42. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
43. Microphysiological systems in absorption, distribution, metabolism, and elimination sciences.
Van Ness KP; Cesar F; Yeung CK; Himmelfarb J; Kelly EJ
Clin Transl Sci; 2022 Jan; 15(1):9-42. PubMed ID: 34378335
[TBL] [Abstract][Full Text] [Related]
44. Pumpless, modular, microphysiological systems enabling tunable perfusion for long-term cultivation of endothelialized lumens.
Tronolone JJ; Lam J; Agrawal A; Sung K
Biomed Microdevices; 2021 Apr; 23(2):25. PubMed ID: 33855605
[TBL] [Abstract][Full Text] [Related]
45. A thermoplastic microfluidic microphysiological system to recapitulate hepatic function and multicellular interactions.
Bale SS; Manoppo A; Thompson R; Markoski A; Coppeta J; Cain B; Haroutunian N; Newlin V; Spencer A; Azizgolshani H; Lu M; Gosset J; Keegan P; Charest JL
Biotechnol Bioeng; 2019 Dec; 116(12):3409-3420. PubMed ID: 30963546
[TBL] [Abstract][Full Text] [Related]
46. Cross-industrial applications of organotypic models.
Kopanska KS; Rimann M
ALTEX; 2022; 39(1):155-158. PubMed ID: 35034134
[TBL] [Abstract][Full Text] [Related]
47. Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies.
Edington CD; Chen WLK; Geishecker E; Kassis T; Soenksen LR; Bhushan BM; Freake D; Kirschner J; Maass C; Tsamandouras N; Valdez J; Cook CD; Parent T; Snyder S; Yu J; Suter E; Shockley M; Velazquez J; Velazquez JJ; Stockdale L; Papps JP; Lee I; Vann N; Gamboa M; LaBarge ME; Zhong Z; Wang X; Boyer LA; Lauffenburger DA; Carrier RL; Communal C; Tannenbaum SR; Stokes CL; Hughes DJ; Rohatgi G; Trumper DL; Cirit M; Griffith LG
Sci Rep; 2018 Mar; 8(1):4530. PubMed ID: 29540740
[TBL] [Abstract][Full Text] [Related]
48. How multi-organ microdevices can help foster drug development.
Esch MB; Smith AS; Prot JM; Oleaga C; Hickman JJ; Shuler ML
Adv Drug Deliv Rev; 2014 Apr; 69-70():158-69. PubMed ID: 24412641
[TBL] [Abstract][Full Text] [Related]
49. Self-Standing Photo-Crosslinked Hydrogel Construct: in vitro Microphysiological Vascular Model.
Manigandan A; Amruthavarshini R P; Sethuraman S; Subramanian A
Cells Tissues Organs; 2022; 211(3):335-347. PubMed ID: 34058730
[TBL] [Abstract][Full Text] [Related]
50. Organ-on-a-chip devices advance to market.
Zhang B; Radisic M
Lab Chip; 2017 Jul; 17(14):2395-2420. PubMed ID: 28617487
[TBL] [Abstract][Full Text] [Related]
51. Application of Immunocompetent Microphysiological Systems in Drug Development: Current Perspective and Recommendations.
Wang X; Kopec AK; Collinge M; David R; Grant C; Hardwick RN; Navratil A; Patel N; Rowan W; Marshall N
ALTEX; 2022 Aug; 40(2):314–336. PubMed ID: 36044561
[TBL] [Abstract][Full Text] [Related]
52. Toward the development of a vibrant, super-aged society: The future of medicine and society in Japan.
Iijima K; Arai H; Akishita M; Endo T; Ogasawara K; Kashihara N; Hayashi YK; Yumura W; Yokode M; Ouchi Y
Geriatr Gerontol Int; 2021 Aug; 21(8):601-613. PubMed ID: 34212470
[TBL] [Abstract][Full Text] [Related]
53. Advances in 3D neuronal microphysiological systems: towards a functional nervous system on a chip.
Anderson WA; Bosak A; Hogberg HT; Hartung T; Moore MJ
In Vitro Cell Dev Biol Anim; 2021 Feb; 57(2):191-206. PubMed ID: 33438114
[TBL] [Abstract][Full Text] [Related]
54. Biological and medical applications of a brain-on-a-chip.
Pamies D; Hartung T; Hogberg HT
Exp Biol Med (Maywood); 2014 Sep; 239(9):1096-1107. PubMed ID: 24912505
[TBL] [Abstract][Full Text] [Related]
55. Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity.
Chang SY; Voellinger JL; Van Ness KP; Chapron B; Shaffer RM; Neumann T; White CC; Kavanagh TJ; Kelly EJ; Eaton DL
Toxicol In Vitro; 2017 Apr; 40():170-183. PubMed ID: 28089783
[TBL] [Abstract][Full Text] [Related]
56. A pharmaceutical industry perspective on microphysiological kidney systems for evaluation of safety for new therapies.
Phillips JA; Grandhi TSP; Davis M; Gautier JC; Hariparsad N; Keller D; Sura R; Van Vleet TR
Lab Chip; 2020 Feb; 20(3):468-476. PubMed ID: 31989145
[TBL] [Abstract][Full Text] [Related]
57. 3D bioprinting for drug discovery and development in pharmaceutics.
Peng W; Datta P; Ayan B; Ozbolat V; Sosnoski D; Ozbolat IT
Acta Biomater; 2017 Jul; 57():26-46. PubMed ID: 28501712
[TBL] [Abstract][Full Text] [Related]
58. The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development.
Tagle DA
Curr Opin Pharmacol; 2019 Oct; 48():146-154. PubMed ID: 31622895
[TBL] [Abstract][Full Text] [Related]
59. Microphysiological systems meet hiPSC technology - New tools for disease modeling of liver infections in basic research and drug development.
Raasch M; Fritsche E; Kurtz A; Bauer M; Mosig AS
Adv Drug Deliv Rev; 2019 Feb; 140():51-67. PubMed ID: 29908880
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
